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Ecstasy (MDMA) and its Relationship with Self-
Report Depression, Anxiety and Schizotypy
Éxtasis (MDMA) y su relación con la depresión,
ansiedad y esquizotipia autoinformadas
Lisa Wood Emma Barkus
Greater Manchester West Mental Health NHS Foundation Trust University of Wollongog
Abstract. Aims: The relationship between ecstasy and affective psychological symptoms
are still subject to debate. We aimed to examine the relationship between Ecstasy use and
self-report depression, anxiety and schizotypy. Design: Data were collected via structured
remote self-report questionnaires. Participants: Participants were split into three groups: a
control group with no ecstasy use, a light ecstasy user group (<50 times), and a heavy ecs-
tasy user group (>50 times). Measurements: Amount and patterns of ecstasy use were recor-
ded, the Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI) measured
depression and anxiety respectively, and schizotypal traits were measured using the schi-
zotypal Personality Questionnaire (SPQ). Findings: It was found that ecstasy use was asso-
ciated with depression, anxiety and schizotypal trait scores. There was no relationship bet-
ween these measures and the level of ecstasy use. Conclusions: Ecstasy use per se was asso-
ciated with self-report depression and anxiety, replicating previous literature. Furthermore,
ecstasy users reported more schizotypal traits, something which had not been investigated
in any previous research. 
Key words: ecstasy, MDMA, 3, 4- methlenedioxymethamphatamine, depression, anxiety,
schizotypy, serotonin.
Resumen. Objetivos: la relación entre el consumo de éxtasis y síntomas afectivos es aún
objeto de debate. Nuestro objetivo es examinar la relación entre el consumo de éxtasis y la
depresión, ansiedad y esquizotipia autoinformadas. Diseño: los datos fueron recogidos a tra-
vés de medidas de autoinforme estructuradas. Participantes: los participantes se dividieron
en tres grupos: grupo control que no consumía éxtasis, grupo de consumidores de éxtasis en
grado bajo (<50 veces), y grupo de consumidores de éxtasis grado alto (> 50 veces).
Instrumentos: se registró la cantidad y patrón de consumo de éxtasis, y se utilizó el
Inventario de Depresión de Beck (BDI) para evaluar depresión, el Inventario de Ansiedad
de Beck (BAI) para evaluar ansiedad, y el Cuestionario de Personalidad Esquizotípica
(SPQ) para evaluar rasgos esquizotípicos. Resultados: el consumo de éxtasis está relaciona-
do con las puntuaciones de rasgo de depresión, ansiedad y esquizotipia. No se ha encontra-
do relación entre las medidas de autoinforme y el grado de consumo de éxtasis.
Conclusiones: el consumo de éxtasis se relaciona con las puntuaciones en depresión y ansie-
dad autoinformada, replicado la evidencia ya existente en la literatura. Más aún, los consu-
midores de éxtasis presentaron mayores puntuaciones en rasgos esquizotípicos, algo que no
se había documentado en ninguna investigación anterior.
Palabras clave: éxtasis, la MDMA, 3, 4 - methlenedioxymethamphatamine, la depresión, la
ansiedad, la esquizotipia, serotonina.
Correspondence to Lisa Wood, Greater Manchester West Mental
Health NHS Foundation Trust, Psychology Services, Bury New Road,
Prestwich, Manchester, M25 3BL.
Introduction
3, 4- Methlenedioxymethamphatamine (MDMA)
is commonly known as ecstasy. It is one of the most
widely used illegal drugs in the UK (Steele,
McCann, & Ricaurte, 1994); and the most popular
with dance enthusiasts (Winstock, Griffiths, &
Stewart, 2001). In the UK approximately half a mil-
lion ecstasy tablets are consumed each weekend
(Saunders, 1995).
Ecstasy depletes 5-HT and 5-Hydroxindolacetic
acid concentration, reduces serotonin transportation
and may cause degeneration of 5-HT axon projec-
tions and nerve terminals (Gouzoulis-Mayfrank,
Dauman, & Sass, 2002). These changes could be
long lasting (Cowan, 2007). Depletion of 5-HT is
found in depression, anxiety, obsessive-compulsive
disorders and psychosis (Naughton, Mulrooney, &
Leonard, 2000; Reneman, et al., 2002).
A relationship between ecstasy use and depres-
sive symptoms has been associated with ecstasy
users per se and current use of the drug using the
Beck Depression Inventory (Beck et al, 1961)
(McCardle, et al., 2004; Medina & Shear, 2007;
Roiser & Sahakian, 2004). In contrast, when using
the Symptom Checklist (SCL – 90; Derogatis,
Rickels & Rock, 1976) and SCL- 90 Revised (SCL-
90 R, Derogatis. 1994) a significant difference has
not been found (Daumann, et al., 2001; Derogatis,
1994; Parrott, et al., 2001; Parrott, Sisk, & Turner,
2000). Daumann et al (2004) for example, reported
that controls and ecstasy users did not differ over a
period of 18 months. The only significant findings
of depression when using the SCL-90-R was report-
ed by Morgan et al (2002).
Anxiety is another experience associated with
ecstasy use. A longitudinal study conducted by
Thomasius et al (2006) assessed current and ex-
ecstasy users, polydrug users and controls and
reported ex-ecstasy users had the highest anxiety
scores, followed by the current ecstasy users and
then the control group. These results have been
replicated by other authors using the SCL-90
(Derogatis, Rickels & Rock, 1976) and the Beck
Anxiety Inventory (BAI, Beck, et al., 1988) ( e.g.
Milani et al., 2004; Beck, et al., 1988; Sumnall,
Wagstaff, & Cole, 2004).
There is evidence that psychotic symptoms may
be induced by recreational drugs with a particular
focus on cannabis (Degenhardt & Hall, 2002; Hides,
et al., 2008). There are also some studies which have
shown ecstasy can lead to a psychotic episode (e.g.
McGuire and Fahy, 1991; Vaiva et al., 2001), and,
similar to cannabis, a younger first use of ecstasy is
associated with an earlier first episode onset of psy-
chosis (Barnett, et al., 2007). However, as illustrat-
ed there is minimal evidence base scrutinising the
link between ecstasy use and psychotic-like symp-
toms.
We hypothesised that ecstasy use will be associat-
ed with self-report depression, anxiety and schizo-
typal traits. The non-ecstasy users will have the low-
est scores on all scales, with the ecstasy users scor-
ing highest. Light ecstasy users will have intermedi-
ary scores between the controls and heavy users.
Method
Participants
Participants were recruited on an opportunity
sample basis with initial contact through email and
other participants being invited using ‘snowball
effect’. They were primarily students from the
University of Manchester. There were 139 partici-
pants: 62 females (mean age 22.48, ± 18-26) and 72
males (mean age 22.47, ± 18 - 31).
Materials
Questions about frequency and pattern of Ecstasy
use and polydrug use were included in the demo-
graphics data collected. Other measures included
were:
1. Beck Anxiety Inventory (BAI, Beck et al,
1988) is a twenty one item list which was used to
measure anxiety. The BAI has been used Ecstasy
studies (e.g. Lamers, Bechara, Rizzo, Ramaekers,
2006) and is a reliable tool to measure anxiety in non-
clinical samples (Creamer, Former, & Bell, 1994)
2. Beck Depression Inventory (BDI, Beck et al
1961) was used to assess depressive symptoms.
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Schizotypal Personality Questionnaire (SPQ,
Raine, 1991) measured schizotypal traits and is
based on the DSM-III_R diagnostic criteria for
schizotypal personality disorder. It has three factors
of Cognitive Perceptual, Interpersonal and
Disorganised are measured. It measure attenuated
psychotic experiences, such as ‘I am sure I am being
talked about behind my back’ (delusion of persecu-
tion) and ‘Are your thoughts sometimes so strong
that you can almost hear them’ (auditory hallucina-
tions).
Procedure
Data from this study came from self-report ques-
tionnaires distributed to University of Manchester
students. Participants completed the questionnaire
via email in their own time and were not compensat-
ed for completing this phase but were offered the
opportunity to take part in a paid component of the
study. Participants gave informed consent for their
data to be used by returning the questionnaires to the
researcher, they were informed of this in the partici-
pant information sheet. This study received ethics
approval from the University of Manchester Senate
Committee.
Statistical Analysis
Data was analysed using SPSS 16.0. Sample
characteristics and polydrug use were compared
using t-tests or ¯Ç tests to check for demographic
differences. Raw data distribution did not differ sig-
nificantly from normal distribution indicated by
Kolmogrow-Smirnow tests. Therefore, one-way
ANOVAs with Scheffe post hoc tests were applied
to investigate differences between Ecstasy usage
and self-report depression, anxiety and schizotypy.
Results will be reported after a Bonferroni adjust-
ment for multiple testing according to an overall
alpha level of 1%.
Results
Participants were split into three groups depend-
ing on ecstasy use as outlined by previous ecstasy
studies, a control group (no ecstasy use), a light
ecstasy users group (<50 times), and a heavy ecstasy
users group (>50 times). Participants were split into
these groups in order to scrutinise degree of use as
done in previous Ecstasy studies (e.g. Parrott et al.,
2001; Parrott et all, 2002). There were 42 non ecsta-
sy using control: 21 females and 21 males with a
mean age of 22.64 (±18 – 27), 60 light ecstasy users,
26 females and 34 males with a mean age of 22.07
(±18 – 31); and, 37 heavy ecstasy users, 15 females
and 22 males with a mean age of 22.44 (±19 – 31).
These groups did not significantly differ in age (F (2,
133) = 0.578, ns) or gender (χ2(2) = 1.173, ns).
Table 1 presents the recreational drug use of all
groups. Alcohol and Popper consumption did not
differ between the non-ecstasy, light ecstasy and
heavy ecstasy using groups, χ2(2) = 2.207, p>0.05
and χ2(2) = 2.473, p>0.05 respectively. However all
other drugs were significantly different between the
three groups; cannabis (χ2(2) = 41.667, p<0.001),
amphetamines (χ2(2) = 48.134, p <0.001), cocaine
(χ2(2) = 38.674, p<0.0005), magic mushrooms
(χ2(2) = 77.871, p<0.001), ketamine χ2(2) = 18.064,
p<0.001) and LSD (χ2(2) = 18.606, p<0.001): those
who used ecstasy were more likely to use other
recreational drugs.
Psychological Symptoms and Ecstasy Usage
The BDI scores were lowest in the control group
(mean=4.33, SD=3.55), the light users were inter-
mediatry (mean=6.95, SD=5.56) and the heavy
users had the highest score (mean=8.81,SD=9.27).
These differences were significant (F (2, 138) =
5.045, p =0.001), Sheffe Post hoc analysis revealed
scores significantly differed between the control
group and the heavy users (p=0.009).
For BAI scores (F (2, 138) = 2.97, p =0.009)
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Table 1. Percentage of Polydrug Use within Each Condition
Non Ecstasy Light Ecstasy Heavy Ecstasy
Users Users Users
Alcohol 97.61% 100% 100%
Cannabis 30.95% 89.29% 97.22% 
Poppers 2.38% 0% 2.85%
Amphetamines 2.38% 8.92% 44.44% 
Cocaine 2.38% 55.35% 94.28% 
Magic Mushrooms 0% 28.57% 36.11% 
Ketamine 0% 30.36% 58.33% 
LSD 0% 23.21% 30.55% 
Scheffe post hoc analysis revealed that the control
and heavy users (p=0.044) differed significantly from
one another. The descriptive statistics were: controls:
mean=5.48, SD=5.15; light users mean=8.10,
SD=7.82; heavy users: mean=9.64, SD=9.86.
For the Cognitive Perceptual dimension of the
SPQ (controls mean=5.98, SD=5.62; light
mean=8.16, SD = 5.62; heavy users mean=8.97,
SD=7.98) and the Interpersonal dimension of the
SPQ (controls: mean=7.17, SD=5.16; heavy users:
mean=8.43, SD=6.23; light users mean=9.15,
SD=6.65) the control group had the lowest scores,
although these differences were not significant. For
the Disorganised dimension of the SPQ (control
mean=3.40, SD=2.76; heavy mean=6.24, SD = 4.42;
light mean=7.10, SD=3.95) a one-way ANOVA (F
(2, 138) = 12.22, p <0.00025) scores differed signif-
icantly between the control and the light users
(p=0.000) and the control and the heavy users
(p=0.003).
Discussion
The main aim of this study was to investigate the
relationship between ecstasy and depression, anxi-
ety and schizotypal traits. We hypothesised ecstasy
use would be associated with a significant increase
in self-report depression, anxiety and schizotypal
traits: the non-ecstasy users would have the lowest
scores, ecstasy users the highest and light ecstasy
users would be an intermediary group.
Ecstasy use had a significant effect on the self-
report depression. On the BAI controls scored sig-
nificantly lower than heavy users. On the BDI the
differences were in the expected direction and
reached significance with the non-ecstasy users
scoring significantly lower than the heavy ecstasy
users after post hoc testing. For the SPQ
Disorganisation dimension the control group scored
significantly lower than the light and heavy users.
For the other two dimensions from the SPQ the dif-
ferences were in the expected direction but these did
not reach significance. These findings support previ-
ous findings that ecstasy has a relationship with
depressive symptoms, (McCardle, et al., 2004;
Parrott, et al., 2002; Win, et al., 2006), anxiety
symptoms (Cole, Sumnall and Wagstaff, 2002) and
psychotic-like symptoms (Vaiva et al, 2001).
The Diathesis-Stress (DS; Parrott, 2006) model
may provide insight into these findings. In this
model proneness to a psychological disorder is an
interaction between an underlying biological vulner-
ability and psychosocial factors. Drug use could be
an example of a psychosocial factor even though it
exerts its effects in a biological manner. According
to the DS model ecstasy use can exacerbate individ-
ual vulnerability to psychological symptoms.
Individual internal and external factors can collec-
tively cause vulnerability, which may explain why
degree of use did not have a significant effect on
individual scores. However, further information
would be needed from participants such as life stres-
sors, personal and family psychiatric history in order
to determine individual vulnerability.
Continued use of ecstasy is thought to lower lev-
els of 5-HT and/or desensitization of the 5-HT sys-
tem (Commins et al, 1987). The role of 5-HT in
depression and anxiety has been well documented
(Naughton, Mulrooney, & Leonard, 2000;
Reneman, et al., 2002), and the drugs which treat
this disorder also target the 5-HT system (e.g.
Harvey, Rudolph,& Preskorn, 2000). The role which
5-HT may play in the onset of psychotic symptoms
is less well defined, although decreases in mood
may increase the likelihood of experiencing delu-
sions (Fowler et al, 2001). Additionally the second
generation atypical antipsychotics, such as
Clozapine, target the 5-HT system (Dursun et al,
2000). Collectively the effects of ecstasy on the
brain are sufficiently non-specific that biological
vulnerability to a psychological disorder could be
expressed after taking ecstasy recreationally.
Particularly if those with a predisposition to a psy-
chological disorder are more sensitive to the possi-
ble long term alterations which ecstasy can induce.
Limitations
One main issue concerning this study and many
other drug-related studies is polydrug use. Ecstasy
users were more likely to have used other drugs
including LSD, Cocaine, Ketamine, Cannabis and
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Magic Mushroom. Previous studies have reported
that ecstasy users are more likely to use cannabis
(Strote, Lee and Wechsler, 2002) and other drugs
such as amphetamine, cocaine and LSD when com-
pared to only cannabis users (Fox et al., 2001). This
illustrates that Ecstasy users are more likely to be
polydrug users. Disentangling the possible interac-
tions between ecstasy effects and other recreational
drugs in terms of their physiological and psycholog-
ical effects is a difficult task.
Furthermore, LSD, Cocaine, Ketamine, Cannabis
and Magic Mushroom are also associated with
depressive, anxious and psychotic-like symptoms
(e.g. Patten et al., 2002) which will confound the
results of the study. It has also been has shown that
polydrug use in conjunction with MDMA can cause
adverse effects (e.g. Williamson, et al., 1997). For
example, cocaine use may increase the neurotoxici-
ty of MDMA (Horan, Gardner, & Ashby, 2000) and
the combined use of LSD and MDMA simultane-
ously is problematic due to their side effects
(Schechter, 1998). However unless studies specifi-
cally recruit individuals who have used or currently
use only one recreational drug they will all be sub-
ject to the confound of polydrug use. Larger studies
may be able to statistically control for polydrug use
however this will only go some way to removing the
individuals differences in drug use and the effects of
this drug use on neurobiological systems. Ecstasy
users score highly on personality traits such as sen-
sation seeking and impulsivity and these traits may
be an indication of why they are more likely to
experiment with recreational drugs (Hanson,
Luciana, & Sullwold, 2008).
In the current study we cannot comment on
whether participants were using multiple drugs in
one session. It is also difficult to quantify how much
ecstasy (and other drugs) an individual ingests both
in one session and lifetime use. It is dependant on
the individual to remember how much they have
taken which can be unreliable (e.g. Dumont &
Verkes, 2006). Moreover, the amount of MDMA in
a tablet is questionable, it has been found that as low
as 22% of the tablet contains MDMA (Galliot-
Guilley, et al., 1999). In further research, careful
recording of factors such as polydrug use, life-stres-
sors, personal and family psychiatric history will
allow for them to be controlled statistically at least
and closer documentation of individual variation
may aid the identification of vulnerability to psycho-
logical symptoms solely caused by ecstasy use.
In conclusion, we presented data of an association
between degree of ecstasy exposure and depressive,
and schizotypal symptoms. The association with
schizotypal symptoms has not been previously doc-
umented. The results from the current study are sup-
ported by the existing literature although further
studies need to focus on why some individuals may
report an increase in these symptoms co-occurring
with ecstasy use.
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